TEM
FDA says go
Tempus AI just got the FDA to clear its ECG-MR product, an AI tool built to help identify undiagnosed mitral regurgitation. In plain English: the company is trying to use software to catch a heart valve problem that might otherwise slip through the cracks.
Why investors should care
FDA clearance is one of those boring-sounding milestones that can actually move the needle. It doesn’t guarantee sales, but it does remove a big regulatory pothole and makes the product much easier to push into the real world.
For Tempus, this is another reminder that it’s trying to be more than a data company with a shiny AI pitch deck. Every clearance helps turn the story from "cool tech demo" into "actual product with a shot at revenue."
Big picture
The healthcare AI race is messy, regulated, and full of companies promising moonshots. Clearing the FDA hurdle won’t make Tempus a household name overnight, but it does give the company something investors like almost as much as hype: permission to sell.